Early Detection Target healthcare providers and oncology clinics that focus on oral cancer screening and high-risk populations (tobacco users, heavy alcohol use, HPV-16). Emphasize BeVigilant OraFusion System as a non-invasive, point-of-care solution that enables earlier intervention and improved patient outcomes.

Regulatory Momentum Leverage FDA Breakthrough Device Designations and CE Mark status to approach partners with accelerated pathways for adoption, including international markets where the product is already available and can be deployed with minimal regulatory friction.

Expansion Opportunities Prioritize markets recently expanded or targeted by the company, such as Germany, and identify regional distributors or Oncology/Hepato-Head & Neck centers that could benefit from localized deployments and joint marketing efforts.

Strategic Alliances Engage with contract research organizations, medical device distributors, and dental/ENT networks to scale adoption; propose co-branded education and training programs to drive clinician confidence and test utilization at the point of care.

Clinical Validation Highlight biomarker-based tumor-initiating and stem cell markers as differentiators to oncologic care pathways; align with hospitals pursuing precision screening programs and payer conversations around cost-effectiveness and reduced late-stage treatment costs.